Elevation Oncology Inc. (NASDAQ:ELEV) currently has a daily average trading volume of 458.83K but it saw 1881251 shares traded on Thursday. With a market cap of 60.70M USD, stock’s current market price of $2.35 came rising about 1.29 while comparing to the previous closing price of $2.32. In past 52 weeks, the stock remained buoying in the range of price level as high as $4.61 and as low as $0.72. In the recent trading on the day, stock has struck highest price mark of $2.40 while lowest mark touched by it was $2.00.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
Sponsored
Taking a look at 20-day trading activity of Elevation Oncology Inc. (ELEV) gives us an average price of $1.30, while its current price level is -49.02% below from 52-week high level whereas it is 225.08% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $1.13 while that of 200 days or SMA-200 reads an average of $1.20. A closer look into the stock’s movement over the week reveals that its volatility is standing at 30.23% during that period while stretching the period over a month that decreases to 16.59%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 79.85 which implies that the stock is in overbought territory.
Elevation Oncology Inc. (ELEV)’s stock is currently under the radar of 3 analysts who are in consensus at a 12-month price target range of between $1.00 and $4.00 for company’s shares. The average price target assigned by the average number of analysts to a stock is a way to gauge worth of any stock in next 52 weeks. And in assigning price target to a stock, some analysts adopt a bearish approach by advocating lower-than-average price target which in this case is $1.00 while some adopt bullish approach by assigning higher-than-average price target which reads the price to top $4.00. Average price target assigned by them is $2.50 which highlights an upside potential of 6.0% for the stock over that period. And to attain the median price target of $2.50 assigned by those analysts, stock has to add about 6.0% of value to its current levels.
Data by FactSet Research shows that 3 analysts have issued their ratings for the stock. 0 of them are in opinions that stock is a Sell, while 0 are advising it as an Overweight. 2 analysts suggested the investors to Buy the stock while 1 advised them to Hold. Recommendations by all of those brokerages imply a consensus rating of Overweight for the stock and that issued by Wall Street to investors is Moderate Buy.
The company’s shares got several price updates from the analyst firms in past one month and most recent of them is from the H.C. Wainwright which initiated the stock as “Buy” in its note to investors issued on December 23, 2021, recommending a price target of $12 for it.
Over the week, ELEV’s stock price is moving 76.69% up while it is 139.80% when we observe its performance for the past one month. Year-to-date it is 147.37% up and over the past year, the stock is showing a downside performance of -6.37%.
The latest quarterly earnings report issued by the company was for quarter ended 12/30/2022, when its quarterly earnings per share (EPS) of -$0.82 beaten by the consensus estimate of -$0.78 for the same. The company is expected to be releasing its next quarterly report in 05/04/2023, for which analysts forecasted an EPS of -$0.68 while estimate for next year EPS is -$2.01. For ELEV, analysts are forecasting an EPS-growth rate of 50.90% for current year and estimate for EPS growth in next year is 21.40%.
Currently, Elevation Oncology Inc.’s total number of outstanding shares is 23.67M with 2.15% of that held by the insiders while 74.41% of its common stock has been owned by the institutions. Stock has a price to book (P/B) ratio of 1.12.
A filing at the U.S. Securities and Exchange Commission revealed that Stichting Pensioenfonds ABP came shrinking its share ownership by 26.97% in the Elevation Oncology Inc. (ELEV) increasing its stake to 1.62% with control over 80259.0 shares in the company.
